MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR)

Multi-center Study for Evaluating the Safety and Efficacy of the MedJ-01 Ridaforolimus Eluting Coronary Stent System (MedJ-01) In Coronary Stenosis Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02828917

Acronym

JNIR

Enrollment

104

Registered

2016-07-12

Start date

2017-01-16

Completion date

2022-08-30

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

de Novo or Restenosis Lesions

Brief summary

MedJ-01 Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising: * A mounted Cobalt Chromium (CoCr) alloy based stent * A Rapid Exchange (RX) Coronary System Delivery System * A Poly n-butyl methacrylate (PBMA) and CarboSil®Polymer matrix coating * Ridaforolimus drug - CAS Registry Number: 572924-54-0 MedJ-01 is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to lesions in vessels with reference diameters of 2.5 mm to 4.25 mm, including complex lesions. JNIR01 is aimed at assessing TLF at one year with the MedJ-01 stent in a Japanese patient population to show equivalence to the results of the BIONICS Trial.

Detailed description

This study aims to evaluate MedJ-01 safety and efficacy for de novo or restenosis lesion with target vessel diameter of 2.5mm to 4.25, for subjects undergoing coronary artery stent implantation. The target population is subjects undergoing PCI for angina (stable or unstable), silent ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis of ≥70%, a positive non-invasive stress test, or FFR ≤0.80 must be present), NSTEMI, and recent subacute STEMI (\>72 hours from initial presentation and stable). Complex lesions are allowed. A maximum of two target vessels and two lesions per vessel may be treated (two lesions separated by up to 10 mm that can be covered by a single stent are considered as one lesion); the total planned study stenting in the coronary tree cannot exceed 100 mm.

Interventions

DEVICEMedJ-01 Ridaforolimus Eluting Coronary Stent System

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patient with indication for PCI including angina (stable/unstable), silent ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis of ≥70%, a positive non-invasive stress test, or FFR ≤0.80 must be present), NSTEMI, or recent subacute STEMI. For subacute STEMI the time of presentation to the first treating hospital, whether a transfer facility or the study hospital, must be \>72 hours prior to enrollment and enzyme levels (CK-MB or Troponin) demonstrating that either or both enzyme levels have peaked. 2. Non-target vessel PCI are allowed prior to enrollment depending on the time interval and conditions as follows: * During Baseline Procedure: * PCI of non-target vessels performed during the baseline procedure itself immediately prior to enrollment if successful and uncomplicated defined as: \<50% visually estimated residual diameter stenosis, TIMI Grade 3 flow, no dissection ≥ NHLBI type C, no perforation, no persistent ST segment changes, no prolonged chest pain, no TIMI major or BARC type 3 bleeding. * Less than 24 hours prior to Baseline Procedure: * Not allowed (see exclusion criterion #2). * 24 hours-30 days prior to Baseline Procedure: * PCI of non-target vessels 24 hours to 30 days prior to enrollment if successful and uncomplicated as defined above. * In addition, in cases where non-target vessel PCI has occurred 24-72 hours prior to the baseline procedure, at least 2 sets of cardiac biomarkers must be drawn at least 6 and 12 hours after the non-target vessel PCI. * If cardiac biomarkers are initially elevated above the local laboratory upper limit of normal, serial measurements must demonstrate that the biomarkers are falling. * Over 30 days prior to Baseline Procedure: * PCI of non-target vessels performed greater than 30 days prior to procedure whether or not successful and uncomplicated. 3. Patient is willing and able to provide informed written consent and comply with follow-up visits and testing schedule. Angiographic inclusion criteria (visual estimate): 4. Target lesion(s) must be located in a native coronary artery with visually estimated diameter of ≥2.5 mm to ≤4.25 mm. 5. Complex lesions are allowed including calcified lesions (lesion preparation with scoring/cutting and rotational atherectomy are allowed), presence of thrombus that is non-occlusive and does not require thrombectomy, CTO, bifurcationlesions (except planned dual stent implantation), ostial RCA lesions, tortuous lesions, bare metal stent restenotic lesions, protected left main lesions. 6. Overlapping stents are allowed with the investigational device (MedJ-01).

Exclusion criteria

1. STEMI within 72 hours (subacute) of initial time of presentation to the first treating hospital, whether at a transfer facility or the study hospital or in whom enzyme levels (either CK-MB or Troponin) have not peaked. 2. PCI within the 24 hours preceding the baseline procedure. 3. Non-target lesion PCI in the target vessel within 12 months of the baseline procedure. 4. History of stent thrombosis. 5. Cardiogenic shock (defined as persistent hypotension (systolic blood pressure \<90 mm/Hg for more than 30 minutes) or requiring pressors or hemodynamic support, including IABP. 6. Subject is intubated. 7. Known LVEF \<30%. 8. Relative or absolute contraindication to DAPT for 12 months (including planned surgeries that cannot be delayed) 9. Subject has an indication for chronic oral anticoagulant treatment (with either vitamin K antagonists or novel anticoagulants - NOACs) 10. Calculated creatinine clearance \<30 mL/min using Cockcroft-Gault equation. 11. Hemoglobin \<10 g/dL. 12. Platelet count \<100,000 cells/mm3 or \>700,000 cells/mm3. 13. White blood cell (WBC) count \<3,000 cells/mm3. 14. Clinically significant liver disease. 15. Active peptic ulcer or active bleeding from any site. 16. Bleeding from any site within the prior 8 weeks requiring active medical or surgical attention. 17. If femoral access is planned, significant peripheral arterial disease which precludes safe insertion of a 6F sheath. 18. History of bleeding diathesis or coagulopathy or will refuse blood transfusions. 19. Cerebrovascular accident or transient ischemic attack within the past 6 months, or any permanent neurologic defect attributed to CVA. 20. Known allergy to the study stent components e.g. cobalt, nickel, chromium, Carbosil®, PBMA, or limus drugs (ridaforolimus, zotarolimus, tacrolimus, sirolimus, everolimus, or similar drugs or any other analogue or derivative or similar compounds). 21. Known allergy to protocol-required concomitant medications such as aspirin, or DAPT (Drugs that inhibit P2Y12 such as clopidogrel and prasugrel), or heparin, or iodinated contrast that cannot be adequately pre-medicated. 22. Any co-morbid condition that may cause non-compliance with the protocol (e.g. dementia, substance abuse, etc.) or reduced life expectancy to \<24 months (e.g. cancer, severe heart failure, severe lung disease). 23. Patient is participating in any other investigational drug or device clinical trial that has not reached its primary endpoint, or plans to participate in any clinical trial. 24. Women who are pregnant or breastfeeding (women of child-bearing potential, defined as females of childbearing potential if they have not undergone a permanent contraceptive operation or they are not postmenopausal, must have a negative pregnancy test within one week before treatment. Permanent contraceptive operation is defined as: hysterectomy, hysterosalpingectomy, or bilateral oophorectomy. The status of a female should be considered as postmenopausal when she has not had a period for 12 consecutive months without an alternative medical cause). 25. Women who intend to become pregnant within 12 months after the baseline procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the baseline procedure). 26. Patient has received an organ transplant or is on a waiting list for an organ transplant. 27. Patient is receiving or scheduled to receive chemotherapy within 30 days before or any time after the baseline procedure. 28. Patient is receiving oral or intravenous immunosuppressive therapy or has known life-limiting immunosuppressive or autoimmune disease (e.g., HIV). Corticosteroids are allowed. Angiographic

Design outcomes

Primary

Measure	Time frame	Description
Target Lesion Failure (TLF)	12 months	TLF is defined as the composite of cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization.

Secondary

Measure	Time frame	Description
Lesion Success at Time of Baseline Procedure	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Lesion Success at time of baseline procedure- outcome
Procedure Success at Time of Baseline Procedure	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Procedure Success at time of baseline procedure- outcome
TLF	30 days, 6 months, and 2, 3, 4 and 5 years	TLF- target lesion failure
Major Adverse Cardiac Events (MACE)	30 days, 6 months, and 1, 2, 3, 4 and 5 years	MACE is the composite rate of cardiac death, any MI or ischemia-driven TLR
Target Vessel Failure (TVF)	30 days, 6 months, and 1, 2, 3, 4 and 5 years	the composite rate of death, target vessel related MI or ischemia-driven TVR
All-cause Mortality	30 days, 6 months, and 1, 2, 3, 4 and 5 years	All-cause mortality outcome
Device Success at Time of Baseline Procedure	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Device Success at time of baseline procedure- outcome
Myocardial Infarction	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Myocardial Infarction (MI)
Target Vessel Related MI	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Target Vessel Related MI outcome
Ischemia-driven TLR	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Ischemia-driven TLR outcome
Ischemia-driven TVR	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Ischemia-driven TVR outcome
Stent Thrombosis	30 days, 6 months, and 1, 2, 3, 4 and 5 years	ARC definite and probable
Cardiac Death	30 days, 6 months, and 1, 2, 3, 4 and 5 years	Cardiac Death outcome

Countries

Japan

Participant flow

Participants by arm

Arm	Count
MedJ-01 Drug Eluting Stent MedJ-01 Ridaforolimus eluting coronary stent system MedJ-01 Ridaforolimus Eluting Coronary Stent System	104
Total	104

Baseline characteristics

Characteristic	MedJ-01 Drug Eluting Stent
Age, Categorical <=18 years	0 Participants
Age, Categorical >=65 years	77 Participants
Age, Categorical Between 18 and 65 years	27 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	104 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants
Race (NIH/OMB) Asian	104 Participants
Race (NIH/OMB) Black or African American	0 Participants
Race (NIH/OMB) More than one race	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) White	0 Participants
Region of Enrollment Japan	104 Participants
Sex: Female, Male Female	21 Participants
Sex: Female, Male Male	83 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	1 / 104
other Total, other adverse events	59 / 104
serious Total, serious adverse events	21 / 104

Outcome results

Primary

Target Lesion Failure (TLF)

TLF is defined as the composite of cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization.

Time frame: 12 months

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
MedJ-01 Drug Eluting Stent	Target Lesion Failure (TLF)	2 Participants

Secondary